Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
02 nov. 2023 09h01 HE
|
Vor Biopharma
Three oral and two poster presentations accepted by ASHCompany to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 oct. 2023 16h01 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of October 1, 2023, the...
Vor Bio to Participate in Upcoming Investor Conferences
25 sept. 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio to Participate in Upcoming Investor Conferences
30 août 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
10 août 2023 16h05 HE
|
Vor Biopharma
Next trem-cel clinical data update expected by year-end 2023VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiationSecured non-exclusive license to Cas9 gene-edited HSCs ...
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
01 août 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow...
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
09 juin 2023 07h30 HE
|
Vor Biopharma
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust enrollment; additional data...
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
05 juin 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman...
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
11 mai 2023 16h05 HE
|
Vor Biopharma
VBP101 clinical data update planned at European Hematology Association (EHA) 2023VCAR33ALLO IND submission on-track for 1H 2023 CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:...
Vor Bio to Participate in Upcoming Investor Conferences
18 avr. 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...